Skip to content

Enliven Therapeutics

US · ELVN #2416 by market cap Listed 1970
41.36 -1.03 -2.43%
Live - 5344 symbols - heartbeat 233s ago · 2026-10-08 08:20
Pre-market 43.00 +3.97%
After-hours 41.36 0.00%
Overnight 41.74 +0.92%
Market cap
3.03B
P/B
3.39
EPS
-1.83
Reader sentiment Are you bullish or bearish on ELVN?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73
    Market Newswire · 2026/8/18
  • Rating change
    H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64
    Market Newswire · 2026/7/9
  • J.P. Morgan Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $75
    Market Newswire · 2026/10/1
  • Rating change
    Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $62
    Market Newswire · 2026/6/2
  • Morgan Stanley Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/10/5
  • Rating change
    William Blair Initiates Enliven Therapeutics(ELVN.US) With Buy Rating
    Market Newswire · 2026/8/18
  • Morgan Stanley Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $70
    Market Newswire · 2026/10/2
  • Rating change
    A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $45 to $80
    Market Newswire · 2026/6/12
  • Rating change
    A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82
    Market Newswire · 2026/8/7
  • Rating change
    JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/6/29
  • Rating change
    Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $59
    Market Newswire · 2026/6/6
  • Rating change
    Stifel Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $60
    Market Newswire · 2026/6/9
  • Rating change
    LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/8/8
  • Rating change
    Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/6/15
  • Rating change
    Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
    Market Newswire · 2026/8/14
  • Rating change
    LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/8/8
  • Rating change
    Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80
    Market Newswire · 2026/7/1
  • Rating change
    Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67
    Market Newswire · 2026/7/22
  • Barclays Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $78
    Market Newswire · 2026/8/18
  • Rating change
    TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
    Market Newswire · 2026/6/13

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:20:04 · For reference only, not investment advice and not tailored to your situation.